Provided by Tiger Fintech (Singapore) Pte. Ltd.

Teva Pharmaceutical

13.88
+0.56504.24%
Volume:6.50M
Turnover:90.32M
Market Cap:15.90B
PE:-9.57
High:14.07
Open:13.80
Low:13.61
Close:13.31
Loading ...

Teva Pharmaceutical US Affiliate, Alvotech Selarsdi Injection Now Available in US

MT Newswires Live
·
21 Feb

Is Teva Pharmaceutical (TEVA) Trading at a Discount?

Insider Monkey
·
19 Feb

Alvotech, Teva Pharmaceutical's Bionsimlar Eye Disorder Potential Treatment Accepted for FDA Review

MT Newswires Live
·
18 Feb

Alvotech and Teva’s BLA filing for AVT06 accepted by FDA

TIPRANKS
·
18 Feb

BRIEF-Alvotech And Teva Announce Filing Acceptance Of U.S. Biologics License Application

Reuters
·
18 Feb

Alvotech Sa - Regulatory Approval Expected by Q4 2025

THOMSON REUTERS
·
18 Feb

Alvotech Sa - FDA Accepts for Review Bla for Alvotech's Biosimilar to Eylea

THOMSON REUTERS
·
18 Feb

Alvotech Sa - Regulatory Approval for Avt06 Expected by Q4 2025

THOMSON REUTERS
·
18 Feb

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for Avt06, a Proposed Biosimilar to Eylea® (Aflibercept)

THOMSON REUTERS
·
18 Feb

Stanley Druckenmiller bought Tesla and these tech stocks last quarter

Dow Jones
·
18 Feb

Teva Announces Significant Holdings Disclosure

TIPRANKS
·
16 Feb

Top Executive Unloads Massive Teva Stock Stake, Raking in Millions!

TIPRANKS
·
15 Feb

Larry Robbins' Strategic Moves: Significant Reduction in Corteva Inc. by 3.62%

GuruFocus.com
·
15 Feb

Teva Reports Change in Officer Holdings

TIPRANKS
·
15 Feb

Why Axsome Therapeutics (AXSM) Is Advancing Today

Insider Monkey
·
12 Feb

Axsome Stock Surges 20% on Auvelity Patent Settlement With Teva

Zacks
·
11 Feb

Sector Update: Health Care Stocks Retreat Monday Afternoon

MT Newswires Live
·
11 Feb

Top Midday Gainers

MT Newswires Live
·
11 Feb

Axsome Therapeutics Resolves Generic Patent Litigation With Teva Over Depression Drug, Analyst Maintains Axsome As 'Top Pick For 2025'

Benzinga
·
11 Feb

Axsome Therapeutics Shares Rise After Agreement with Teva Pharmaceuticals Ends Litigation

Dow Jones
·
10 Feb